Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Company Overview

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products. The company also develops treatments for rare blood disorders, including hemophilia, and hormone-related conditions such as growth disorders.

The company traces its history to the development of insulin production in Denmark during the 1920s. Novo Nordisk was formed in 1989 through the merger of Nordisk Gentofte and Novo Industri. Its products are marketed internationally, with operations and commercial activities serving patients and health care providers across numerous regions, including North America, Europe, Asia and other global markets.

Key Stats

• Today's Range: $39.54 to $40.10
• 50-Day Range: $37.31 to $48.65
• 52-Week Range: $35.12 to $64.16
• Volume: 15.24 million shs
• Average Volume: 10.44 million shs
• Market Capitalization: $178.42 billion
• P/E Ratio: 9.77
• Dividend Yield: 2.05%
• Price Target: $59.44
• Consensus Rating: Hold

Novo Nordisk A/S Stock Analysis - MarketRank™

Novo Nordisk A/S scored higher than 79% of companies evaluated by MarketBeat, and ranked 103rd out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 5 buy ratings, 16 hold ratings, and 5 sell ratings.

Upside Potential

Novo Nordisk A/S has a consensus price target of $59.44, representing about 48.7% upside from its current price of $39.96.

Amount of Analyst Coverage

Novo Nordisk A/S has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Novo Nordisk A/S are expected to remain at $3.42 per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novo Nordisk A/S is 9.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novo Nordisk A/S is 9.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.82.

Price to Earnings Growth Ratio

Novo Nordisk A/S has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novo Nordisk A/S has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the float of Novo Nordisk A/S has been sold short.

Short Interest Ratio / Days to Cover

Novo Nordisk A/S has a short interest ratio ("days to cover") of 3.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novo Nordisk A/S has recently increased by 18.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novo Nordisk A/S pays a meaningful dividend of 2.08%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novo Nordisk A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.31

News Sentiment

Novo Nordisk A/S has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for Novo Nordisk A/S this week, compared to 7 articles on an average week.

Search Interest

Only 52 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

MarketBeat Follows

35 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 192% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Novo Nordisk A/S is held by insiders.

Percentage Held by Institutions

11.54% of the stock of Novo Nordisk A/S is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Record date for 8/25 Dividend: 8/17/2026
• Ex-Dividend for 8/25 Dividend: 8/17/2026
• Dividend Payable: 8/25/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NVO
• CIK: 353278
• Web: www.novonordisk.com
• Phone: (454) 444-8888
• Fax: 45-4449-0555
• Employees: 69,505
• Year Founded: 1923

Price Target and Rating

• Average Price Target for Novo Nordisk A/S: $59.44
• High Price Target: $175.00
• Low Price Target: $38.00
• Potential Upside/Downside: +48.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.09
• Trailing P/E Ratio: 9.77
• Forward P/E Ratio: 11.68
• P/E Growth: 1.33
• Net Income: $15.51 billion
• Net Margins: 35.36%
• Pretax Margin: 45.31%
• Return on Equity: 58.61%
• Return on Assets: 20.91%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 0.87
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $46.80 billion
• Price / Sales: 3.81
• Cash Flow: $4.79 per share
• Price / Cash Flow: 8.35
• Book Value: $6.58 per share
• Price / Book: 6.07

Miscellaneous

• Outstanding Shares: 4,465,000,000
• Free Float: 4,461,875,000
• Market Cap: $178.42 billion
• Optionable: Optionable
• Beta: 0.76